303 related articles for article (PubMed ID: 33998104)
1. Role of systematic pelvic and para-aortic lymphadenectomy in delayed debulking surgery after six neoadjuvant chemotherapy cycles for high-grade serous ovarian carcinoma.
Lopes A; Genta MLND; da Costa Miranda V; Aranha A; Lopez RVM; Piato DSAM; Anton C; Carvalho FM; Del Pilar Esteves Diz M; Carvalho JP
J Obstet Gynaecol Res; 2021 Aug; 47(8):2737-2744. PubMed ID: 33998104
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer.
Song N; Gao Y
Int J Gynecol Cancer; 2019 May; 29(4):761-767. PubMed ID: 30850437
[TBL] [Abstract][Full Text] [Related]
3. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
[TBL] [Abstract][Full Text] [Related]
5. Should We Abandon Systematic Pelvic and Paraaortic Lymphadenectomy in Low-Grade Serous Ovarian Cancer?
Simon V; Ngo C; Pujade-Lauraine E; Ferron G; Pomel C; Leblanc E; Nadeau C; Ray-Cocquard I; Lecuru F; Bonsang-Kitzis H
Ann Surg Oncol; 2020 Oct; 27(10):3882-3890. PubMed ID: 32246309
[TBL] [Abstract][Full Text] [Related]
6. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Gynecol Oncol; 2012 Sep; 126(3):381-6. PubMed ID: 22609747
[TBL] [Abstract][Full Text] [Related]
8. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
[TBL] [Abstract][Full Text] [Related]
10. Risks and benefits of systematic lymphadenectomy during interval debulking surgery for advanced high grade serous ovarian cancer.
Benoit L; Koual M; Le Frère-Belda MA; Zerbib J; Fournier L; Nguyen-Xuan HT; Delanoy N; Bentivegna E; Bats AS; Azaïs H
Eur J Surg Oncol; 2022 Jan; 48(1):275-282. PubMed ID: 34753619
[TBL] [Abstract][Full Text] [Related]
11. Effects of pretreatment radiological and pathological lymph node statuses on prognosis in patients with ovarian cancer who underwent interval debulking surgery with lymphadenectomy following neoadjuvant chemotherapy.
Komatsu H; Iida Y; Osaku D; Shimogai R; Chikumi J; Sato S; Oishi T; Harada T
J Obstet Gynaecol Res; 2021 Jan; 47(1):152-158. PubMed ID: 32830400
[TBL] [Abstract][Full Text] [Related]
12. Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
Bizzarri N; du Bois A; Fruscio R; De Felice F; De Iaco P; Casarin J; Vizza E; Chiantera V; Corrado G; Cianci S; Magni S; Ferrari D; Giuliani D; Harter P; Ataseven B; Bommert M; Perrone AM; Scambia G; Fagotti A
Gynecol Oncol; 2021 Jan; 160(1):56-63. PubMed ID: 33168305
[TBL] [Abstract][Full Text] [Related]
13. What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
Benoit L; Zerbib J; Koual M; Nguyen-Xuan HT; Delanoy N; Le Frère-Belda MA; Bentivegna E; Bats AS; Fournier L; Azaïs H
Gynecol Oncol; 2021 Sep; 162(3):667-673. PubMed ID: 34217542
[TBL] [Abstract][Full Text] [Related]
14. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
15. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
16. Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery: a double-institution case-control study.
Fagotti A; De Iaco P; Fanfani F; Vizzielli G; Perelli F; Pozzati F; Perrone AM; Turco LC; Scambia G
Ann Surg Oncol; 2012 Oct; 19(11):3522-7. PubMed ID: 22644507
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
Vincent L; Jankowski C; Ouldamer L; Ballester M; Bendifallah S; Bolze PA; Akladios C; Costaz H; Lavoué V; Canlorbe G; Collinet P; Touboul C; Huchon C; Bricou A; Dridi S; Padéano MM; Bengrine L; Arnould L; Coutant C;
Eur J Surg Oncol; 2020 Sep; 46(9):1689-1696. PubMed ID: 32417154
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
[TBL] [Abstract][Full Text] [Related]
19. Interval debulking surgery following neo-adjuvant chemotherapy for stage IVB ovarian cancer using neutral argon plasma (PlasmaJet™).
Butler-Manuel S; Lippiatt J; Madhuri TK
Gynecol Oncol; 2014 Dec; 135(3):622-3. PubMed ID: 25450152
[TBL] [Abstract][Full Text] [Related]
20. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
Panici PB; Maggioni A; Hacker N; Landoni F; Ackermann S; Campagnutta E; Tamussino K; Winter R; Pellegrino A; Greggi S; Angioli R; Manci N; Scambia G; Dell'Anna T; Fossati R; Floriani I; Rossi RS; Grassi R; Favalli G; Raspagliesi F; Giannarelli D; Martella L; Mangioni C
J Natl Cancer Inst; 2005 Apr; 97(8):560-6. PubMed ID: 15840878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
